They need to sell out. They have a great product that isn’t selling. Why? Because customers fear they won’t survive.
Does ASXC have a future?
ASXC Stock 12 Months Forecast
Based on 2 Wall Street analysts offering 12 month price targets for Asensus Surgical in the last 3 months. The average price target is $1.50 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 536.67% change from the last price of $0.24. :)
Asensus Surgical Announces Collaboration with NVIDIA to Enhance Augmented Intelligence Capabilities of the ISU
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced a collaboration with NVIDIA to accelerate the development of Asensus’s Intelligent Surgical Unit™ (ISU™) and improve its ability to deliver novel clinical intelligence to surgeons.
Asensus will utilize a broad suite of NVIDIA tools to enhance the augmented intelligence capabilities of its ISU. Asensus’s ISU is built with NVIDIA accelerated computing technology and has been bringing real-time augmented intelligent features — such as digital tags, 3D measurement, and enhanced camera control — to surgeons since 2021.
“We’re thrilled to collaborate with NVIDIA to enhance the machine vision and image analytics capabilities of the ISU, as well as the processing speed and precision of its augmented intelligence capabilities. Utilizing NVIDIA’s advanced technologies will allow us to further improve the ISU’s augmented intelligence capabilities and the roadmap of our innovative clinical applications,” said Anthony Fernando, Asensus Surgical President and CEO. “Through this collaboration, Asensus is furthering its vision to enhance clinical intelligence in surgery through the use of advanced augmented intelligence tools.”
As part of the collaboration, both companies will have early access to relevant product roadmaps, fostering synergistic development. Furthermore, Asensus and NVIDIA plan to jointly define innovative business models for the development, deployment, and commercialization of digital surgical solutions.
“The healthcare industry, and in particular digital surgery, is becoming one of the largest data generating industries. NVIDIA brings a domain-specific full stack edge AI computing platform, Holoscan, to medtech innovators looking to optimize real-time data and image processing to help solve complex problems and improve surgeon decision-making,” said David Niewolny, Director of Healthcare Business Development at NVIDIA. “As a leading FDA cleared solution in soft-tissue abdominal surgery, Asensus’s ISU is a perfect platform to leverage NVIDIA’s software-defined architecture to accelerate innovation and deliver new products to surgeons faster via software-as-a-medical-device applications.”
Moving up nice and steady.
More news: Asensus and KARL STORZ to Market the Intelligent Surgical Unit and Co-Develop New Vision and Instrument Platforms
70s and dumping, lmfao.
SUPER BUY ASXC
Soon their SENHANCE surgical units are going to be in a number of US HOSPITALS side by side with Da Vinci. SENHANCE is the safest most sophisticated Robotic AI AR vision tracking surgical platform developed since Da Vinci came to market some 20 years ago.
Go back to sleep. I am out.
say what? did you see what it did today? tomorrow same thing.. are you shorting? if so, you lost everything
Study showing significantly lower instrument costs than da Vinci with comparable learning curve and console times.
In this real-world comparative assessment from four U.S. and European hospitals, results showed that the learning curve of gynecological Senhance®? surgeons compared to those of da Vinci gynecological surgeons achieved lower median instrument costs with comparable console times. Case costs between Senhance and laparoscopic-assisted vaginal hysterectomy cases were comparable as well. This further supports how Digital Laparoscopy with Senhance is reducing the economic limitations of current robotic systems so that the benefits of our technology can reach more patients.
Learn more about the assessment here:
Yea sure bud that’s comical.
My guess is they tried to bring it down to scare all of the investors. I kept buying as it went down all the way from $6 I now have 34k shares at an average of $3. This will be a $40 stock in a year or so. I feel a buy out is coming soon. Great time to buy the company before it goes back up to $20